Product Description
Veterinary products are important tools in the prevention and control of animal diseases. The definition of veterinary products may vary from one country to another; for OIE purposes, they include vaccines, veterinary medicines, such as antimicrobial agents, and diagnostic kits.
The Veterinary Products for Companion Animals market revenue was xx Million USD in 2019, grew to xx Million USD in 2023, and will reach xx Million USD in 2031, with a CAGR of xx during 2024-2031.
Considering the influence of COVID-19 on the global Veterinary Products for Companion Animals market, this report analyzed the impact from both global and regional perspectives. From production end to consumption end in regions such as North America, Europe, China, and Japan, the report put emphasis on analysis of market under COVID-19 and corresponding response policy in different regions.
This report also analyzes the strategies for different companies to deal with the impact of COVID-19 in detail to seek a path to recovery.
Under COVID-19 Outbreak, how the Veterinary Products for Companion Animals Industry will develop is also analyzed in detail in Chapter 1.8 of this report.
Major Players in Veterinary Products for Companion Animals market are:
Elanco Animal Health
Animalcare Group
Zoetis
Merck Animal Health
Parnell
Ouro Fino Saude
Vetoquinol
Virbac
Ceva
Bayer Animal Health
Dechra Veterinary Products
Boehringer Ingelheim
Meiji
Most important types of Veterinary Products for Companion Animals products covered in this report are:
Medicines
Vaccine
Other
Most widely used downstream fields of Veterinary Products for Companion Animals market covered in this report are:
Dogs
Cats
Other
Major Regions or countries covered in this report:
North America
Europe
China
Japan
Middle East and Africa
South America
India
South Korea
Southeast Asia
Others
In Chapter 3.4, the report provides analysis of the reasons behind price fluctuations.
In chapters 5, 6, and 7, the impact of COVID-19 on the different regions in both production and consumption end and SWOT analysis are pointed out.
In Chapters 8, the report presents company's recent development and strategies to deal with the impact of COVID-19.